Biomedical Bondings product DendroPrime for coating of metal implants show excellent biological safety properties
Press release: Biomedical Bonding’s DendroPrime is a coating that prevents soft-tissue in-growth to commercial implants inserted close to tendons and joints, improving mobility after hand surgery. Recent ISO 10993 tests performed by RISE confirms DendroPrime’s excellent biological safety properties including skin irritation and cytotoxicity results.
DendroPrime is an innovative coating product that prevents clinically used medical implants from soft-tissue in-growth upon surgical insertion. In Sweden, up to 40% of all finger fractures needs to be re-operated due to complications from tissue adhesions when ordinary metal plate and screws are used. Tissue ingrowth strongly decreases mobility and function at the fracture site, leading to patient suffering and increased societal burden. Fixation of hand fractures is the most expensive fracture subgroup for the society.
The DendroPrime has pre-clinically been verified to display an anti-adhesion feature that eliminate tissue scarring as well as soft-tissue and tendon ingrowth. Due to its bone-like properties, the DendroPrime also act as an implant “cloaking” product decreasing patient awareness of alien metal plates and screws. Surgeons have confirmed it to be a unique and attractive solutions adding value to traditionally used orthopedic implants in conjugation to tendons and joints.
“The confirmation of DendroPrimes excellent biological safety properties is an important step on our road to commercialization. Our product has the potential to become a gamechanger minimizing the high numbers of post-surgical complications and re-operation after finger fractions”, says Founder and CEO, Prof. Michael Malkoch.
The tests performed by RISE are key deliverables for the collaborative project “Coated metal implants for improved mobility after hand surgery” between KTH Royal Institute of Technology, South Stockholm General Hospital and Biomedical Bonding AB. The activities are funded by Vinnova-Medtech4Health-Swelife and Knut and Alice Wallenberg foundation.
For more information, please contact:
Michael Malkoch, CEO and Founder
Phone: +46 (0) 8 121 56 755
E-mail: michael.malkoch@biomedicalbonding.com
Homepage: www.biomedicalbonding.com
Biomedical Bonding AB is a platform-based Swedish MedTech company that develops cutting-edge medical adhesive fixators and novel surgical methodologies with focus on the ever-growing market of hard tissue restorations. The technological platform, Bonevolent™, is market disruptive and stands for a paradigm shift in personalized surgical interventions. BMB´s vision is to become the dominant global provider of unique adhesive products suited for fracture fixation and dental restoration market. BMB´s Bonevolent™ products are easy-to-use by clinicians, will increase patient safety, save costs and resources for health care and society as a whole. BMB is a privately held company headquartered in Stockholm, Sweden.
